Last updated on April 16, 2014 at 12:31 EDT

Alliance for Regenerative Medicine Announces Agenda for Regen Med Investor Day

March 12, 2013

- Taking place April 17, 2013 in New York City; Agenda includes keynote talks, focused disease sessions with KOL participation and presentations from 16 top regenerative medicine companies -

WASHINGTON, March 12, 2013 /PRNewswire/ — The Alliance for Regenerative Medicine (ARM) today announced the agenda for its Regen Med Investor Day, the first investor event organized specifically for the regenerative medicine sector. The event will take place on April 17 at the Harmonie Club, 4 East 60(th) Street, New York, NY.

This one-day, high-impact program will provide institutional investors and life science analysts with insight from the industry’s leading small- and mid-cap companies as well as exclusive access to regenerative medicine’s top stakeholders.

Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at lparsons@alliancerm.org if interested in attending.

    7:30am   Breakfast &

    8:00am  Welcome Remarks

             Keynote Talk -
             Kieran Murphy,
             VP, President &
             CEO, GE
             Healthcare Life
    8:10am   Sciences

             Keynote Talk -
             Jeff Jonas,
             President, Shire
    8:30am   Medicine

             Introduction -
             Jason Kolbert,
             Analyst, Maxim
    8:50am   Group

    9:00am   Clinical Outlooks

                               Jason Kolbert, Senior Biotechnology
                               Analyst, Maxim Group (moderator)

                               Douglas Losordo, MD, Adjunct
                               Professor in Medicine-Cardiology,
                               Northwestern University

                               Eduardo Marban, MD, Director,
                               Cedars-Sinai Heart Institute

                               Leslie Miller, MD, Chair, College Of
                               Medicine Dean's Office, University
                               of South Florida

    9:55am  Break

             Medicine in
             Wound Healing &
    10:10am  Engineering

                               Ted Tenthoff, Managing Director &
                               Senior Biotechnology Analyst, Piper
                               Jaffray (moderator)

                               Vincent Falanga, MD, Professor,
                               Boston University School of

                               Will Li, MD, President & Medical
                               Director, The Angiogenesis

                               Thomas Serena, MD, FACS, CEO and
                               Medical Director SerenaGroup

    11:05am  Therapeutics for
             a Broad Range of
             CNS Diseases

                               Ren Benjamin, Ph.D., Managing
                               Director & Senior Biotechnology
                               Analyst, Burrill & Company

                               Sean Savitz, MD, Professor of
                               Neurology, University of Texas
                               Medical School, UTHealth

    12:00pm  Plated Lunch &

             Presentation -
             G. Steven
             Burrill, CEO,
             Burrill &
    12:45pm  Company

    1:00pm   Cytori
             Therapeutics -
             Chris Calhoun,

    1:15pm   Athersys -Gil
             Van Bokkelen,
             Chairman & CEO

    1:30pm   Mesoblast -
             Silviu Itescu,
             CEO & President

    1:45pm   Juventas
             Therapeutics -
             Rahul Aras,
             President & CEO

             Biosciences -
             Dan Orlando,
             Chief Commercial
    2:00pm   Officer

    2:15pm   NeoStem -Robin
             Smith, Chairman
             & CEO

    2:30pm   Pluristem
             Therapeutics -
             Zami Aberman,
             Chairman & CEO

    2:45pm   Cytomedix -
             Rosendale, CEO

    3:00pm  Afternoon Break

    3:15pm   Sangamo
             BioSciences -
             Edward Lanphier,
             President & CEO

    3:30pm   BioTime
             Acquisition Corp
             -Thomas Okarma,
             President & CEO

    3:45pm   Advanced Cell
             Technology (ACT)
             -Gary Rabin,
             Chairman & CEO

    4:00pm   StemCells Inc. -
             Martin McGlynn,
             President & CEO

    4:15pm   Organogenesis -
             Geoff MacKay,
             President & CEO

    4:30pm   Organovo -Keith
             Murphy, CEO

    4:45pm   Tigenix -Eduardo
             Bravo, CEO

    5:00pm   Mimedx -Michael
             Senken, CFO

             Program Wrap-up
             - Ted Tenthoff,
             Director &
    5:15pm   Biotechnology

             Analyst, Piper

    5:30pm   Networking

This meeting is co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group and in partnership with Life Science Advisors and Blaise Group International.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.

Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087

SOURCE Alliance for Regenerative Medicine

Source: PR Newswire